Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4184228 | 0.87 | FAAH (0.46) | FAAHGPR119KDM4EPKMGAA | |
| SCHEMBL4182815 | 0.81 | FAAH (0.67) | FAAHGPR119KDM4EPKM | |
| SCHEMBL4179626 | 0.81 | FAAH (0.66) | FAAHGPR119KDM4EPKM | |
| SCHEMBL4182555 | 0.77 | FAAH (0.57) | FAAHGPR119KDM4EPKM | |
| SCHEMBL13875455 | 0.75 | NMT1 (0.37) | FAAH | |
| SCHEMBL389003 | 0.75 | FAAH (0.53) | FAAHGPR119KDM4EPKM | |
| SCHEMBL20077254 | 0.74 | GPR119 (0.51) | FAAHGPR119KDM4EPKM | |
| SCHEMBL7446229 | 0.73 | GPR119 (0.53) | FAAHGPR119KDM4EPKM | |
| SCHEMBL8617529 | 0.73 | GPR119 (0.53) | FAAHGPR119KDM4EPKM | |
| SCHEMBL15085741 | 0.72 | GPR119 (0.59) | FAAHGPR119KDM4EPKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111778-A1 | 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| EP-1954137-A4 | 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-17 | — | — | EP | disclosed |
| EP-1954137-A2 | 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007061862-A2 | 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111778-A1 | 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase | FAAH, FAAH2, HCRTR2 | FAAH 1/4885GPR119 159/4885KDM4E 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.